New combination immune therapy for cancer is effective and has fewer side effects, study finds

NewsGuard 100/100 Score

Google "chemotherapy side effects" and the results abound. Nausea, anemia, infection, fertility problems, kidney problems, mouth sores. The list goes on and on.

The seemingly inevitable downside of treating one's cancer always seems to be a reduction in their quality of life. But a new Northwestern Medicine study found that a new combination immune therapy treatment not only extended cancer patients' lives better than other treatments, it also was less toxic to their overall health than other drugs on the market, providing an added quality-of-life benefit.

Historically in cancer, most new treatments that extend survival come at a cost. In this study, we found it's actually easier on patients, so it has the double benefit."

David Cella, lead author, chair of the Department of Medical Social Sciences at Northwestern University Feinberg School of Medicine

The findings will be published January 12 in the journal Lancet Oncology.

The quality-of-life study follows an earlier New England Journal of Medicine (NEJM) study, which found a combination chemotherapy treatment of nivolumab plus cabozantinib doubled the survival rate in patients with previously untreated advanced renal-cell carcinoma when compared to the current standard first-line treatment with sunitinib.

The Lancet Oncology study examined patient-reported symptoms and side effects from that study. It found those who were given the new treatment, nivolumab plus cabozantinib (experimental), reported their symptoms were stable or had improved while on the treatment, while those taking the existing treatment, sunitinib (control), reported a deterioration in their health status and being bothered by side effects.

"Immune therapy is revolutionizing the treatment of advanced kidney cancer," Cella said. "For the first time in decades, we are seeing benefits to both survival and quality of life with these new treatments." People with kidney cancer have more effective treatment options than ever before. Not only are they living longer, they are living better."

Funding for the study was provided by Bristol Myers Squibb in collaboration with Ono Pharmaceutical and with Exelixis, Ipsen Pharma and Takeda Pharmaceutical.

Journal reference:

Cella, D., et al. (2022) Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial. Lancet Oncology.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New study advocates for de-escalating breast cancer surgery in women aged 55 and older